A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimers Disease (AD) DISCOVER
Study of Posiphen in Subjects with Early Alzheimer's Disease (AD) DISCOVER
Sponsor: Alzheimer's Disease Cooperative Study ADCS
Enrolling: Male and Female Patients
IRB Number: AAAR6583
U.S. Govt. ID: NCT02925650
Contact: Evelyn Dominguez: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information: This study is an early phase study of a medication for Alzheimer's Disease, with examination of cerebrospinal fluid.
This study is closed
Investigator
Lawrence Honig, MD, PhD
Do You Qualify?
Are you between the ages of 55-85 (inclusive)? Yes No
Do you have Early AD (including Mild Cognitive Impairment due to Alzheimers disease (MCI-AD) or mild Alzheimers disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Evelyn Dominguez
edd5@cumc.columbia.edu
212-305-2371
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE